New Meta-Analysis Reassesses Long-Term Survival Outcomes After Mohs Surgery for Melanoma

A systematic review of 13 comparative studies and more than 500,000 patients finds Mohs micrographic surgery associated with favorable long-term survival in selected melanoma cases — with no significant difference at five years, and no randomized trials behind the numbers. For the Mohs laboratory, the value of this paper is as much in what it does not prove as in what it suggests.

Wide local excision (WLE) remains the standard surgical treatment for melanoma. Mohs micrographic surgery (MMS) — in which excised tissue is mapped, frozen, sectioned, and examined microscopically during the procedure so that margins can be assessed while the patient is still in the office — is used as a tissue-sparing alternative in selected cases. It is considered most often where preserving tissue matters most and margins are hardest to judge clinically, particularly on the head and neck, and for melanoma in situ and lentigo maligna–type disease.

That role has long raised a fair question: does the way the margin is assessed change long-term outcomes, or does Mohs simply get chosen for different kinds of patients and tumors? A new systematic review and meta-analysis published online in Dermatologic Surgery on October 28, 2026, set out to compare survival after MMS versus WLE across the available comparative literature. Its findings deserve a careful read — especially from the laboratory side of the practice, where margin assessment actually happens.

What the study did

The authors systematically reviewed the literature in PubMed, Embase, and the Cochrane Library and performed a meta-analysis of comparative studies of MMS versus WLE for melanoma. Thirteen comparative studies, including more than 500,000 individuals, met the criteria for inclusion.

Survival was compared using adjusted hazard ratios (HRs) — estimates that account, as far as the underlying studies allowed, for differences between the groups being compared. An HR below 1.0 favors the Mohs group; an HR of 1.0 means no difference; and a result is conventionally described as statistically significant when its 95% confidence interval (CI) does not cross 1.0. The analysis looked separately at overall survival (OS) — survival from any cause — and disease-specific survival (DSS) — survival from melanoma itself — both over the long term and at the five-year mark, with subgroup results by site and melanoma subtype.

Long-term results favored Mohs — five-year results did not differ

Over the long term, MMS was associated with both higher overall survival and higher disease-specific survival than WLE. The long-term overall survival result was modest (HR 0.93); the disease-specific result was larger (HR 0.63). The overall survival association was mainly driven by melanoma of the head and neck, and within that group, particularly by invasive disease. A favorable association was also reported for the lentigo maligna subtype.

The five-year results tell a different story, and they belong in any honest summary of this paper: at five years, there was no significant difference between MMS and WLE in either overall survival or disease-specific survival. Readers who see only the long-term headline numbers are missing half of what the study actually found.

Table: Adjusted hazard ratios for Mohs micrographic surgery versus wide local excision. HR < 1.0 favors Mohs. Results are statistically significant when the 95% CI does not cross 1.0 — which is why the two five-year rows, whose intervals cross 1.0, are reported as no significant difference. Source: Dermatologic Surgery, published online October 28, 2026 (PMID 42937688).

Why this matters in the Mohs laboratory

Survival papers are usually read by surgeons. This one should also be read by the people who cut, stain, and prepare the tissue — because the proposed advantage of Mohs is, at its core, a laboratory claim: that complete, mapped margin assessment during the procedure allows tumor clearance to be confirmed while sparing uninvolved tissue. If outcomes differ, the difference runs through the lab. Four points matter most:

• Complete margin assessment — the sections must represent the margin that was actually excised. Mapping, inking, orientation, and embedding are not clerical steps; a poorly oriented or incompletely represented section weakens the very assessment the technique depends on.
• Frozen-section interpretation is complex — melanoma on frozen sections is harder to interpret than basal or squamous cell carcinoma. Melanocytes can be difficult to distinguish from background skin changes, especially in sun-damaged head and neck skin — exactly the population driving this meta-analysis. Section quality, thickness, and artifact control directly affect how confidently a margin can be read.
• MART-1 immunohistochemistry — immunostaining for MART-1 (Melan-A) is commonly used to help identify melanocytes in Mohs sections for melanoma. Used well, it can clarify an ambiguous margin; used without controls and consistent protocols, it can also highlight benign melanocytes and invite overcalling. Reproducible staining, validated controls, and documented protocols are part of the quality story behind any outcome claim.
• Tissue preservation in the head and neck — the clearest signal in this analysis was in head and neck melanoma, where every millimeter of spared tissue can affect function and reconstruction. That is the setting where careful, stage-by-stage tissue processing has its most visible payoff — and where a missed margin also carries its highest cost.

None of this means laboratory technique explains the survival associations reported here — the study did not measure lab variables. It means that if a practice offers Mohs for melanoma, the credibility of that offering rests on laboratory quality that can be shown, not assumed.

Read the numbers honestly: the limitations

The authors' results are associations from observational evidence, and the article on this website will describe them that way — as outcomes Mohs was "associated with," not outcomes Mohs is proven to cause. Three limitations should accompany any use of these findings:

• No randomized trials. Every included study was observational. There are no randomized controlled trials comparing MMS and WLE for melanoma in this analysis. Randomization is what balances the unknown differences between groups; without it, some of any observed difference may reflect who received which treatment, not the treatment itself.
• Selection and baseline differences. Patients selected for Mohs differ from patients treated with wide excision. In prior systematic reviews of invasive melanoma — including the 2024 review by Williams and colleagues in the Journal of the European Academy of Dermatology and Venereology — Mohs patients have tended to be older and to have thinner melanomas than WLE patients. Adjusted hazard ratios reduce this problem; they do not eliminate it, because adjustment can only account for factors the original studies measured.
• The five-year results were null. A long-term difference with no significant five-year difference is a pattern that calls for caution, not celebration. It is compatible with a genuine late benefit in selected patients, with differences in follow-up and case mix between studies, or with both. The data do not distinguish among those explanations.

For those reasons, this meta-analysis does not establish Mohs as superior to wide local excision for melanoma, and it should not be quoted that way — in marketing copy, in patient materials, or in conversation. What it supports is narrower and still useful: in selected patients, particularly with head and neck melanoma, Mohs was associated with favorable or comparable long-term survival in the available comparative literature.

What this means in practice

• Continue to treat case selection as a clinical decision made case by case — site, subtype, stage, and patient factors — not as a conclusion this paper makes for the practice.
• Document the laboratory side as carefully as the surgical side: mapping accuracy, section quality, staining protocols and controls for MART-1, and how ambiguous margins were resolved. If outcomes are ever audited, those records are the evidence.
• Use precise language with patients and referring clinicians: "associated with favorable long-term survival in selected patients in observational studies" is accurate; "proven to improve survival" is not.
• Watch for the evidence that would actually change the picture: prospective comparative data, analyses that account more fully for tumor thickness and stage at presentation, and longer, more uniform follow-up.

For histotechnologists and Mohs technicians specifically, the practical takeaway is professional rather than clinical: melanoma cases are the most interpretation-sensitive work in the Mohs laboratory. Training, competency documentation, and quality control for frozen-section melanoma work — including immunohistochemistry — are not administrative extras. They are the foundation under every outcome figure a paper like this reports.

Conclusion

This meta-analysis is the strongest comparative summary currently available for Mohs surgery in melanoma, and its long-term findings — overall survival HR 0.93 and disease-specific survival HR 0.63, concentrated in head and neck disease — will rightly attract attention. Its five-year findings, which showed no significant difference, and its entirely observational evidence base deserve exactly the same prominence. Read whole, the paper supports Mohs as a reasonable, tissue-sparing option in selected melanoma cases with outcomes that compare favorably over the long term. It does not prove superiority, and responsible practice — in the operating room and in the laboratory — will present it no other way.

References

1. Primary source: Systematic review and meta-analysis comparing Mohs micrographic surgery versus wide local excision for melanoma. Dermatologic Surgery. Published online October 28, 2026. PMID: 42937688. DOI: 10.1097/DSS.0000000000005402. PubMed: https://pubmed.ncbi.nlm.nih.gov/42937688/
2. Supporting source: Williams et al. Systematic review of Mohs micrographic surgery for invasive melanoma. Journal of the European Academy of Dermatology and Venereology (JEADV). 2024.
3. Supporting source: American Academy of Dermatology melanoma clinical guideline (as cited in the editorial review).